Latest Commercial Expansion News

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

TZ Limited has completed a A$1.5 million capital raise at a premium, appointed David Sampaklis as Group CEO with significant shareholding, and repaid A$1 million of debt, positioning itself for growth in data centre security.

Straker Ltd announces a pivotal leadership shift with the appointment of David Sowerby and Indiver Nagpal as Co-CEOs, marking a new era focused on commercial expansion and AI innovation. Founder Grant Straker transitions to a strategic board role to steer the company’s AI future.

Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.